Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia
NCT00770237 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2019-08-19
Summary
In this study, we will compare cue-reactivity in smokers with and without schizophrenia and the influence of smoking cues on responding for cigarette puffs under a PR schedule of reinforcement. Given the high prevalence of smoking among individuals with schizophrenia, understanding some of the environmental factors that serve to maintain nicotine dependence is a critical step in improving smoking cessation treatment outcomes. Establishing and validating a laboratory model of cue-elicited responsivity and cigarette self- administration will allow the investigation of the efficacy of anti-craving medications in people with schizophrenia.
Specific Aims 1) To compare the effects of smoking versus neutral cues on craving, mood, and autonomic responsivity in smokers with schizophrenia and smokers without schizophrenia. 2) To compare the effects of smoking versus neutral cues on the reinforcing efficacy of tobacco cigarettes in smokers with schizophrenia and smokers without schizophrenia.
Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
The ratio of 3-HC/cotinine is a phenotypic biomarker of the rate of nicotine metabolism, which has been shown to be associated with level of nicotine dependence, various smoking behaviors, and treatment outcome (Ho \& Tyndale, 2007). We will correlate the primary measures with the 3-HC/cotinine ratio to explore possible relationships for future study.
Conditions
- Schizophrenia
- Nicotine Dependence
Interventions
- BEHAVIORAL
-
Smoking Cues
In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
- BEHAVIORAL
-
Neutral Cues
In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
collaborator NIH -
University of Maryland, Baltimore
lead OTHER
Principal Investigators
-
Deanna L Kelly, Pharm.D, BCPP · University of Maryland, College Park
-
Stephen J Heishman, Ph.D. · National Institute on Drug Abuse (NIDA)
Study Design
- Purpose
- DIAGNOSTIC
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-10-31
- Primary Completion
- 2010-12-31
- Completion
- 2010-12-31
Countries
- United States
Study Locations
More Related Trials
-
Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia
NCT01034085 ·Status: COMPLETED
-
Examining Persistence in Smokers With Schizophrenia
NCT03346291 ·Status: COMPLETED ·Phase: NA
-
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
NCT01037075 ·Status: COMPLETED
-
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics
NCT01246128 ·Status: WITHDRAWN
-
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia
NCT00407277 ·Status: COMPLETED ·Phase: NA
-
The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
NCT00373126 ·Status: COMPLETED ·Phase: PHASE4
-
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia
NCT01046526 ·Status: COMPLETED
-
Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality
NCT01031433 ·Status: COMPLETED
-
Minocycline and Tobacco Craving in Smokers With Schizophrenia
NCT02968602 ·Status: COMPLETED ·Phase: PHASE4
-
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
NCT00136760 ·Status: COMPLETED ·Phase: PHASE2
-
Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness
NCT00500695 ·Status: COMPLETED ·Phase: PHASE1
-
Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder
NCT00382915 ·Status: COMPLETED
-
Brain Circuits in Schizophrenia and Smoking
NCT01425684 ·Status: COMPLETED
-
Music to Reduce Use of Smoking in Patients With Schizophrenia
NCT03190161 ·Status: COMPLETED ·Phase: NA
-
Acute Effects of Exercise in Smokers With Schizophrenia
NCT01635075 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
NCT00307203 ·Status: COMPLETED ·Phase: PHASE4
-
Circuitry-Guided Smoking Cessation in Schizophrenia
NCT03281629 ·Status: COMPLETED ·Phase: NA
-
The Effects of Nicotine on Cognition in Schizophrenia
NCT00383747 ·Status: COMPLETED ·Phase: PHASE4
-
Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2
NCT00135772 ·Status: COMPLETED
-
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
NCT01186471 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
NCT02069392 ·Status: COMPLETED ·Phase: NA
-
Novel Smoking Cessation Drug for Schizophrenia
NCT02230384 ·Status: COMPLETED ·Phase: PHASE2
-
Very Low Nicotine Cigarettes in Smokers With Schizophrenia
NCT02019459 ·Status: COMPLETED ·Phase: PHASE2
-
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
NCT02128919 ·Status: COMPLETED ·Phase: NA
-
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
NCT01214005 ·Status: COMPLETED ·Phase: PHASE2